0001356090-26-000017
SEC filingPapzimeos commercial launch drove explosive 1634% revenue growth to $23.3M while narrowing operating and net losses significantly year-over-year, reflecting successful transition from R&D expense to inventory capitalization, though operating cash burn accelerated amid commercialization ramp-up.
Precigen's Q1 2026 results mark a pivotal shift to commercial-stage biotech, with revenue exploding 1633.9% to $23.3 million from $1.3 million in the prior-year quarter. This surge stems directly from the FDA approval and launch of Papzimeos, our recently approved commercial product, enabling initial sales from pre-launch inventories. Unlike prior periods where production costs were expensed as R&D, these costs are now capitalized as inventory and recognized as cost of products sold upon revenue generation. This accounting change, combined with commercial traction, ignited the revenue engine while dramatically narrowing losses.
Operating income improved 73.5% to -$6.0 million from -$22.6 million, yielding an operating margin of -25.8%. The primary driver was the reclassification of Papzimeos manufacturing costs out of R&D expenses, as noted in Management's Discussion. Following FDA approval, these production costs transitioned from R&D expensing to balance sheet inventory, directly reducing the operating loss burden and positioning the company for improved margins as inventory is sold. Net income followed suit, improving 85.4% to -$7.9 million from -$54.2 million, with diluted EPS at -$0.02 versus -$0.18. This reflects the absence of prior-year warrant liability charges, mainly driven by Precigen’s stock price rise and paid-in-kind dividends on Series A Preferred Stock.